{"id":"W2170071316","doi":"10.1200/jco.2005.02.129","title":"Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":true,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre; Jewish General Hospital; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Gefitinib; Cancer; Rash; Chemotherapy; Prostate-specific antigen; Randomized controlled trial; Clinical trial; Oncology; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0288391,0.0001816475,0.005386187,0.0002279734,0.00004110759,0.00000222505,0.0003180621,0.0002445013,0.0001291607],"category_scores_gemma":[0.0231079,0.000096027,0.001004404,0.0003393445,0.0009594617,0.000130996,0.0001048959,0.001041103,1.034205e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004603933,"about_ca_system_score_gemma":0.02108077,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.0305822,"about_ca_topic_score_gemma":0.1156192,"domain_scores_codex":[0.9842064,0.00409784,0.009764312,0.0002296547,0.001435525,0.0002662517],"domain_scores_gemma":[0.9794281,0.01032238,0.008339437,0.0001993666,0.001472054,0.0002386298],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8953471,0.02301393,0.01013899,0.00006323003,0.002185403,0.00004114852,0.0005334127,0.0001945971,0.0009083469,0.00003892418,0.002402874,0.06513207],"study_design_scores_gemma":[0.943438,0.03265828,0.01344219,0.0003064754,0.00104977,0.000007039155,0.00020794,0.00009592615,0.0005159667,0.0001196738,0.008081337,0.00007739686],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865708,0.003121604,0.000001733499,0.005399203,0.001860074,0.0025796,0.0001201365,0.000001676755,0.0003451238],"genre_scores_gemma":[0.9886882,0.009074048,0.0001448683,0.0002488692,0.001484334,0.00008613583,0.000003388767,0.00001262576,0.0002575855],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08503705,"threshold_uncertainty_score":0.9995113,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3188633390056988,"score_gpt":0.5975672502723148,"score_spread":0.278703911266616,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}